The DOI matches its Crossref record.
Absorption, metabolism, and excretion of salicylazosulfapyridine in man
Abstract
Salicylazosulfapyridine (SASP), 4 Gm. daily, was ingested by 9 healthy subfects for 10 days, and the serum concentrations and urinary and fecal excretion of the parent drug and its metabolites were studied. SASP is extensively metabolized by reductive cleavage of the azo linkage, presumably by the action of the gut flora. The sulfapyridine moiety thus formed is subfect to N 4‐acetylation or ring hydroxylation followed by confugation to glucuronic acid, or both. The 5‐aminosalicylic acid moiety is N‐acetylated. The steady‐state serum concentrations of the parent drug and its metabolites, obtained by Day 5, for SASP ranged from 4.7 to 45 p.g per milliliter (median 12 p.g per milliliter), for total sulfapyridine metabolites from 37 to 92 p.g per milliliter (median 50 p.g per milliliter), and for total 5‐aminosalicylic acid metabolites to less than 2 p.g per milliliter. The urinary excretion of unchanged SASP ranged from 1.7 to 10 per cent of the dose. About 80 per cent of the dose was excreted in the urine as metabolites of sulfapyridine and one third of the dose was excreted as the metabolite of 5‐aminosalicylic acid. Feces did not contain any SASP, but about 5 per cent of the dose was present as metabolites of sulfapyridine and an unknown amount as metabolites of 5‐aminosalicylic acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
The gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.009 · Cited by 618
Fleisher, D., Li, C., Zhou, Y., Pao, L., & Karim, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00004 · Cited by 506
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
Wang, Y., Parker, C. E., Bhanji, T., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000543.pub4 · Cited by 494
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Wang, Y., Parker, C. E., Feagan, B. G., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000544.pub4 · Cited by 483
The gut microbiome: an orchestrator of xenobiotic metabolism
Collins, S. L., & Patterson, A. D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.001 · Cited by 348
Klotz, U., Maier, K., Fischer, C., & Heinkel, K. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032602 · Cited by 322
Klotz, U. (1985) · Clinical Pharmacokinetics · doi:10.2165/00003088-198510040-00001 · Cited by 277
Tetrahydrobiopterin biosynthesis as an off-target of sulfa drugs
Haruki, H., Pedersen, M. G., Gorska, K. I., Pojer, F., & Johnsson, K. (2013) · Science · doi:10.1126/science.1232972 · Cited by 101
Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis
Pounder, R. E., Craven, E. R., Henthorn, J. S., & Bannatyne, J. M. (1975) · Gut · doi:10.1136/gut.16.3.181 · Cited by 49
van Hogezand, R. A., Kennis, H. M., van Schaik, A., Koopman, J. P., van Hees, P. A. M., & van Tongeren, J. H. M. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf01740669 · Cited by 40
Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers
Rust, C., Bauchmuller, K., Bernt, C., Vennegeerts, T., Fickert, P., Fuchsbichler, A., & Beuers, U. (2006) · Gut · doi:10.1136/gut.2005.077461 · Cited by 20
Metadata
- Authors
- Schröder, H., & Campbell, D. E. S.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1972-07
- Volume
- 13
- Issue
- 4
- Pages
- 539-551
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2415775034
- Cited by
- 323
- References
- 0
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.